loading
前日終値:
$10.95
開ける:
$10.98
24時間の取引高:
4.91M
Relative Volume:
0.92
時価総額:
$972.55M
収益:
$20.65M
当期純損益:
$-192.65M
株価収益率:
-4.2124
EPS:
-2.59
ネットキャッシュフロー:
$-134.39M
1週間 パフォーマンス:
-1.09%
1か月 パフォーマンス:
-1.89%
6か月 パフォーマンス:
+77.69%
1年 パフォーマンス:
+59.97%
1日の値動き範囲:
Value
$10.90
$10.99
1週間の範囲:
Value
$10.90
$11.09
52週間の値動き範囲:
Value
$2.8647
$11.40

Verve Therapeutics Inc Stock (VERV) Company Profile

Name
名前
Verve Therapeutics Inc
Name
セクター
Healthcare (1163)
Name
電話
(978) 501-3026
Name
住所
201 BROOKLINE AVENUE, BOSTON
Name
職員
274
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
VERV's Discussions on Twitter

VERV を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
VERV
Verve Therapeutics Inc
10.91 985.11M 20.65M -192.65M -134.39M -2.59
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.81 120.40B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
542.52 61.30B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.53 41.06B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
564.59 34.29B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.55 27.09B 3.81B -644.79M -669.77M -6.24

Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-15 アップグレード Cantor Fitzgerald Neutral → Overweight
2024-04-08 開始されました H.C. Wainwright Buy
2023-04-13 開始されました Canaccord Genuity Buy
2023-02-01 開始されました Cantor Fitzgerald Neutral
2022-12-15 開始されました Goldman Sell
2022-10-06 開始されました Credit Suisse Neutral
2022-08-25 アップグレード Stifel Hold → Buy
2022-06-17 開始されました BMO Capital Markets Outperform
2022-02-18 開始されました RBC Capital Mkts Outperform
2021-09-24 開始されました Stifel Hold
2021-07-12 開始されました Guggenheim Buy
2021-07-12 開始されました JP Morgan Neutral
2021-07-12 開始されました Jefferies Buy
2021-07-12 開始されました William Blair Outperform
すべてを表示

Verve Therapeutics Inc (VERV) 最新ニュース

pulisher
05:03 AM

What drives Verve Therapeutics Inc. stock priceExponentially increasing returns - Jammu Links News

05:03 AM
pulisher
03:06 AM

What analysts say about Verve Therapeutics Inc. stockHigh-impact investment strategies - Jammu Links News

03:06 AM
pulisher
Jul 18, 2025

Is Verve Therapeutics Inc. a good long term investmentFree Market Dynamics Reports - Jammu Links News

Jul 18, 2025
pulisher
Jul 18, 2025

Verve Therapeutics Inc. Stock Analysis and ForecastAccelerated profit realization - Jammu Links News

Jul 18, 2025
pulisher
Jul 15, 2025

Verve Offers $416K Award To GC Amid Lilly Acquisition - Law360

Jul 15, 2025
pulisher
Jul 15, 2025

Verve Therapeutics grants retention bonuses to CFO and COO amid pending acquisition - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

Verve Therapeutics grants retention bonuses to CFO and COO amid pending acquisition By Investing.com - Investing.com South Africa

Jul 15, 2025
pulisher
Jul 15, 2025

Verve Therapeutics Announces Retention Bonus Program for Executives - TipRanks

Jul 15, 2025
pulisher
Jul 14, 2025

Why Verve Therapeutics Inc. stock attracts strong analyst attentionDaily Trade Opportunity - beatles.ru

Jul 14, 2025
pulisher
Jul 13, 2025

Verve Therapeutics, Inc. (VERV): A Bull Case Theory - MSN

Jul 13, 2025
pulisher
Jul 07, 2025

Prime Medicine soars as Jones sees it as an acquisition target - Seeking Alpha

Jul 07, 2025
pulisher
Jul 06, 2025

Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why - MSN

Jul 06, 2025
pulisher
Jun 27, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

Jun 27, 2025
pulisher
Jun 27, 2025

BMO Capital Downgrades Verve Therapeutics to Market Perform, $13.50 Price Target - MarketScreener

Jun 27, 2025
pulisher
Jun 24, 2025

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly - MSN

Jun 24, 2025
pulisher
Jun 23, 2025

Lilly To Acquire Verve For One-Time Cardiovascular Treatments - Insider Monkey

Jun 23, 2025
pulisher
Jun 20, 2025

Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week - AOL.com

Jun 20, 2025
pulisher
Jun 20, 2025

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV) - TradingView

Jun 20, 2025
pulisher
Jun 19, 2025

What is the Intent Behind Eli Lilly's Recent M&A Deals Spree? - Yahoo Finance

Jun 19, 2025
pulisher
Jun 18, 2025

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc.VERV - Business Wire

Jun 18, 2025
pulisher
Jun 18, 2025

Verve Therapeutics Stock Price, Quotes and Forecasts - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly Acquires Verve Therapeutics In $1.3 Billion Deal - Finimize

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly (LLY) Moves to Acquire Verve Therapeutics in $1B Deal - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Lilly to acquire Verve Therapeutics for $1.3 billion - C&EN

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

Verve Therapeutics’ SWOT analysis: gene-editing stock shows promise amid challenges - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly (LLY) Enters Gene-Editing Space with Verve Therapeutics Acquisition - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports - MSN

Jun 18, 2025
pulisher
Jun 18, 2025

Verve Therapeutics downgraded to Hold from Buy at Canaccord - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly nears $1.3B deal for Verve Therapeuticsreport - MSN

Jun 18, 2025
pulisher
Jun 18, 2025

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView

Jun 18, 2025
pulisher
Jun 18, 2025

Beyond Obesity: Eli Lilly’s Genetic Medicine Bet On Verve Therapeutics - Forbes

Jun 18, 2025
pulisher
Jun 18, 2025

This Verve Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

HC Wainwright Downgrades Verve Therapeutics (VERV) Rating to Neutral | VERV Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Jefferies Downgrades Verve Therapeutics (VERV), Lowers Price Tar - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Verve Therapeutics (VERV): Downgrade and Updated Price Target | - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Lilly to acquire Verve Therapeutics to advance gene editing treatments - World Pharmaceutical Frontiers

Jun 18, 2025
pulisher
Jun 18, 2025

Lock In The 81.5% Run: Initiating Verve With A Sell (NASDAQ:VERV) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 18, 2025

Canaccord Genuity Downgrades Verve Therapeutics to Hold From Buy - marketscreener.com

Jun 18, 2025
pulisher
Jun 18, 2025

HC Wainwright Downgrades Verve Therapeutics to Neutral From Buy, $25 Price Target - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Verve Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Hold Rating on Verve Therapeutics Acquisition by Eli Lilly: Fair Valuation with Low Competing Bid Potential - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Verve Therapeutics (VERV) Downgraded After Acquisition Agreement | VERV Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Lilly Eyes Future of One-Time Cardiovascular Health with $1.3B Verve Therapeutics Acquisition - geneonline.com

Jun 18, 2025
pulisher
Jun 18, 2025

Verve Therapeutics downgraded to Hold from Buy at Jefferies - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Jefferies cuts Verve Therapeutics stock rating on Lilly acquisition news - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

M&A News: Verve Therapeutics Stock (VERV) Rallies 75% on News of Potential Acquisition by Eli Lilly - The Globe and Mail

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly to acquire for Verve Therapeutics for up to $1.3B - MSN

Jun 18, 2025
pulisher
Jun 18, 2025

Verve Therapeutics (VERV) Downgraded Following Acquisition Annou - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High? - MSN

Jun 18, 2025
pulisher
Jun 17, 2025

Eli Lilly Bets Big On Gene Editing With Verve Deal - Finimize

Jun 17, 2025

Verve Therapeutics Inc (VERV) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$21.88
price down icon 0.59%
$35.59
price up icon 0.34%
$102.56
price down icon 1.55%
$26.20
price down icon 5.18%
$110.02
price down icon 0.92%
biotechnology ONC
$294.55
price up icon 1.45%
大文字化:     |  ボリューム (24 時間):